Clinical trials: Central Retinal Vein Occlusion
Retinal Vein Occlusion
Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept
In patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and safety in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in United States and GALILEO study performed in…
- Trial name
- HERMES (NCT02880644)
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Age-related Macular Degeneration, Retinal Vein Occlusion
Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections
Evaluation if a computer-based tutorial ("MacInfo" tool) improves the patients' knowledge about intravitreal drug injections, associated risks, and the underlying diseases of treatment-naive patients.
- Conditions
- Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT04142164
- Testing
- MacInfo presentation
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Prim. Prof. Dr. Oliver Findl, MBA
Central Retinal Vein Occlusion
Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)
Ranibizumab (Lucentis, Genentech) is an off-label drug used for the clinical treatment of central retinal vein occlusion, which is one of the most common retinal vascular disorders.
- Trial name
- NCT01303276
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Glaucoma, Retinal Vein Occlusion
Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)
The difficulty to measure blood flow in humans is connected with the necessity of using not invasive, reliable and reproducible techniques.
- Trial name
- AO-LDV (NCT03525132)
- Testing
- Laser Doppler Velocimetry + Optic Adaptative Camera
- Where
- France
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Branch Retinal Vein Occlusion
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome.
- Trial name
- NCT02478515
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Nagoya City University
Wet Macular Degeneration, Diabetic Macular Edema
Artificial Intelligence Diagnostic Aid
The investigators have worked with software designers to develop a software that allows us to analyse current adherence to guidelines on Ophthalmic conditions such as Age related Macular Degeneration (AMD), Diabetic Macular Edema…
- Conditions
- Wet Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- AID (NCT05675540)
- Testing
- Macusense Assessment Software
- Where
- United Kingdom
- Volunteers
- 422 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Central Retinal Vein Occlusion
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion.
- Trial name
- NCT01178697
- Testing
- Bevasizumab, Triamcinolone Acetonide
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Macular Edema, Retinal Vein Occlusion
Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Central and branch retinal vein occlusions are major causes of visual loss. Hemorrhage and capillary nonperfusion, when they involve the macula, can contribute to visual loss, but the major cause is macular edema.
- Trial name
- LVO (NCT00407355)
- Testing
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Peter A Campochiaro, MD
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Retinal Vein Occlusion
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion.
- Trial name
- NCT01581151
- Testing
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Burke, MPH
Central Retinal Vein Occlusion
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO).
- Trial name
- TRUST (NCT03981549)
- Testing
- Autologous Bone Marrow CD34+ Stem Cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Emmes Company, LLC
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Branch Retinal Artery Occlusion, Central Retinal Artery Occlusion
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
Canadians fear loss of vision more than any other disability. Vision loss has an enormous impact on quality-of-life and is extremely costly from a societal and economic perspective.
- Conditions
- Branch Retinal Artery Occlusion, Central Retinal Artery Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
- Trial name
- NCT01348633
- Where
- Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Retinal Vein Occlusion
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
- Trial name
- FALCON (NCT01809236)
- Testing
- Conbercept
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Age-related Macular Degeneration, Central Retinal Vein Occlusion
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates.
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01640171
- Testing
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Retina Vitreous Associates of Florida
Neovascular Age-related Macular Degeneration, Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT06176963
- Testing
- SB11 PFS
- Where
- 3 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Samsung Bioepis Co., Ltd.